Spravato (esketamine) Treatment Center
Depression affects millions of people worldwide, with a significant number experiencing treatment-resistant depression (TRD) that doesn’t respond to traditional therapies. However, an exciting breakthrough treatment modality known as intranasal esketamine, marketed as Spravato, has emerged as a promising option for patients struggling with depression.
Tidewater Total Mind Care is excited to announce that we are now a certified treatment center in the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. We offer Spravato (esketamine) for adults who are suffering from depression in a comfortable and private office setting under the supervision of a board-certified psychiatrist. This treatment is designed to be:
-
In the few years since its approval, intranasal Spravato (esketamine) has gained recognition as an innovative, safe and effective treatment option for adults suffering from depression. There is also evidence it can work faster than other treatment options alone such as oral antidepressants, and some respond to this treatment as quickly as after the first treatment.
-
Esketamine is the first new therapy indicated for treatment-resistant depression in over 30 years and was approved on March 5, 2019 by the FDA. It is the only ketamine-based product approved by the FDA for depression.
-
Average insurance criteria:
Major Depressive Disorder (treatment-resistant)
Inadequate response to two or more antidepressants
Current use of an oral anti-depressant medication
Most patients will have Spravato covered by their insurance
We now offer Buy and Bill for patients with Medicare
SPRAVATO® Patient Video: Nicole’s Story
SPRAVATO® helped Nicole’s treatment-resistant depression. Now, she’s resuming her education and sharing her story
SPRAVATO® Patient Video: Allison’s Story
Allison’s son tried many oral antidepressants without relief. Now, because of SPRAVATO®, Allison’s son is starting to feel like himself again.
Amenities for our patients include:
Complimentary guest Wi-Fi
Reclining chairs and blankets
Reading materials
TV with access to streaming services
Essential oil aromatherapy
Handicap access
Free parking
Water, coffee, snacks
FAQs
-
The first FDA-approved nasal spray specifically for adults with treatment-resistant depression.
SPRAVATO® targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. The exact way that SPRAVATO® works is unknown. SPRAVATO® is taken with an oral antidepressant.
-
Spravato is covered by most insurance providers and Tidewater Total Mind Care is in network with most of these covered insurance plans.
If you are eligible and commercially insured, the SPRAVATOwithMe Savings Program may help you pay as little as $10 per treatment for SPRAVATO® medication costs.
We also offer the Buy and Bill option for patients with Medicare.
-
While SPRAVATO® and ketamine are chemically related, SPRAVATO® is not the same as IV ketamine. Only SPRAVATO® has undergone extensive controlled clinical trials that earned FDA approval of the medicine for use in adults with TRD and to treat depressive symptoms in adults with MDD with acute suicidal ideation or behavior.
Spravato is a painless experience - no needles required!
-
In the comfort of our tranquil office, conveniently located in Sarasota. Tidewater Total Mind Care is a REMS-certified treatment center for Spravato.
-
Each treatment session lasts a minimum of 2 hours. Our nursing staff monitors patient vitals and treatment response throughout each session.
Weeks 1-4 include two sessions per week. Weeks 5-8 include one session per week. Weeks 9 and beyond include one session per week or every 2 weeks depending on individual need.